Written by Julia Thayer, Associate Director, Advocacy There have been several exciting advocacy developments in recent weeks, especially at the state level, where advocates and coalition partners continue advancing efforts to expand access to biomarker testing and improve patient care. Tennessee Becomes the 24th State with Comprehensive Biomarker Testing Coverage Earlier in May, Tennessee officially … Continued
Uterine (or endometrial) cancer is the most common type of gynecologic cancer, with more than 886,000 women living with the disease in the U.S., according to National Cancer Institute’s SEER Cancer Statistics. As Ovarian Cancer Research Alliance funds research that aims to cure ovarian and related gynecologic cancers, we are here for those impacted by … Continued
After losing her friend Mary Anne Kobylka to ovarian cancer, Stacey Dickinson continues raising funds for research as captain of Team Mary Anne at SummeRun and through her business, Play the Day®. Hope is at the heart of Stacey Dickinson’s tireless efforts to raise funds for ovarian cancer research, which began more than two decades … Continued
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
We Believe There’s a Better Way to Do Research So we created it. OCRA has launched the most ambitious initiative in our history. We believe it represents a fundamentally new way for research to work—one with the potential to accelerate discovery in gynecologic cancers while serving as a model for breakthroughs across all diseases. We … Continued
Platform, powered by AWS, connects patients, researchers, and clinicians to accelerate breakthroughs in gynecologic cancers [NEW YORK, NY – May 8, 2026] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting … Continued
On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research that aims to improve ovarian cancer survival rates On World Ovarian Cancer Day the Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Research Alliance (OCRA) is … Continued
Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’s 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued
Written by Julia Thayer, Associate Director, Advocacy FY2027 Budget Update & Advocacy Momentum As we continue through appropriations season, we wanted to share a quick update on the President’s proposed FY2027 budget and what it means for our community. While we’re still awaiting full details, there are a few key takeaways to highlight. A quick … Continued
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
